TrialThe Journal of infectious diseases2023

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.

Kevin M Tuffy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.